

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)  SHEET 1 of 2	<b>COMPLETE IF KNOWN</b>	
	Application Number	10/140,541
	Confirmation Number	6529
	Filing Date	05/07/2002
	First Named Inventor	Michael Philip Clark
	Group Art Unit	1614
	Examiner Name	
	Attorney Docket Number	8570

**U. S. PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
W	1	US-5,776,954	07/07/1998	De Laszlo et al.	
W	2	US-5,686,455	11/11/1997	Adams et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T*
W	3	WO 00/10563 A1	03/02/2000	SmithKlineBeecham Corp.		
W	4	WO 97/47618 A1	12/18/1997	Merck & Co. Inc.		
W	5	WO 01/12621 A1	02/22/2001	Vertex Pharmaceuticals Inc.		
W	6	WO 00/26209 A1	05/11/2000	Novartis AG		
W	7	WO 99/03837 A1	01/28/1999	Orto-McNEIL Pharmaceuticals, Inc.		
W	8	WO 95/13067 A1	05/18/1995	SmithKlineBeecham Corp.		

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
W	9	DINARELLO, C. A., "Interleukin-1", Reviews of Infectious Diseases, Vol. 6, No. 1, pp. 51-95, 1984.	
W	10	MAINI, R. et al., "Infliximab (chimeric anti-tumour necrosis factor $\alpha$ monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial", <u>The Lancet</u> , Vol. 354, pp. 1932-39, 1999.	
W	11	WEINBLATT, M. E. et al., "A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptors:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate", <u>The New England J. of Medicine</u> , Vol. 340, No. 4, pp. 253-259, 1999.	
W	12	PELLETIER, J.P., et al., "Coordinate Synthesis of Stromelysin, Interleukin-1, and Oncogene Proteins in Experimental Osteoarthritis", <u>Amer. J. of Pathology</u> , Vol. 142, No. 1, pp. 95-105, 1993.	
W	13	FARAHAT, M.N. et al., "Cytokine Expression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis", <u>Annals of the Rheumatic Diseases</u> , Vol. 52, pp. 870-875, 1993.	
W	14	TIKU, K. et al., "Articular Chondrocytes Secrete IL-1, Express Membrane IL-1, and Have IL-1 Inhibitory Activity", <u>Cellular Immunology</u> , Vol. 140, pp. 1-20, 1992.	
W	15	WEB, G. R., et al., "Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis", <u>Osteoarthritis and Cartilage</u> , Vol. 5, pp. 427-437, 1997.	
W	16	WESTACOTT, A. F., et al., "Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis", <u>Osteoarthritis and Cartilage</u> , Vol. 8, pp. 213-221, 2000.	
W	17	MCDANIEL, M.L., et al., "Cytokines and Nitric Oxide in Islet Inflammation and Diabetes", <u>Proc. Soc. Exp. Biol. Med.</u> , Vol. 211, No. 1, pp. 24-32, 1996.	
W	18	RANKIN, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Necrosis Factor alpha Antibody (CDP571) in Rheumatoid Arthritis", <u>British J. of Rheumatology</u> , Vol. 34, pp. 334-342, 1995.	
W	19	STACK, W.A., et al., "Randomised controlled trial of CDP571 antibody to tumour necrosis factor- $\alpha$ in Crohn's disease", <u>The Lancet</u> , Vol. 349, No. 9051, pp. 521-4, 1997.	
W	20	HAN, J., et al., "Regulation of MEF2 by p38 MAPK and Its Implication in Cardiomyocyte Biology", <u>Trends Cardiovasc Med.</u> , Vol. 10, No. 1, pp. 19-22, 2000.	
W	21	HUNTER, J.J., et al., "Signaling Pathways for Cardiac Hypertrophy and Failure", <u>The New England J. of Medicine</u> , Vol. 341, No. 17, pp. 1276-1283, 1999.	

M	22	BEHR, T.M., et al., "Sustained Activation of Cardiac P38 Mitogen Activated Protein Kinase in the Development of Heart Failure: Pre-mature Mortality is Abolished by Chronic P38 Inhibition in Rat Model of Cardiac Hypertrophy and Failure", <u>Basic Science</u> , Vol. 102, pp. 289, 2000.	
M	23	SHIMAMOTO, A., et al., "Inhibition of P38 Mitogen-Activated Protein Kinase Suppresses Interleukin-1 $\beta$ -Expression and Prevents Progression of Cardiac Hypertrophy and Congestive Heart Failure in Rats", <u>Basic Science</u> , Vol. 102, pp. 289, 2000.	
M	24	AUKRUST, P., et al., "Cytokine Network in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy", <u>Am. J. Cardiol.</u> , Vol. 83, No. 3, pp. 376-382, 1999.	
M	25	SINGH, A., et al., "Inducible Nitric Oxide Synthase in Vascular Smooth muscle Cells From Prehypertensive Spontaneously Hypertensive Rats", <u>Am. J. Hypertens.</u> , Vol. 9, No. 9, pp. 867-77, 1996.	
M	26	DINARELLO, C.A., "Interleukin-1 and Interleukin-1 Receptor Antagonist", <u>Supplement to Nutrition</u> , Vol. 11, No. 5, pp. 492-494, 1995.	
M	27	ARENZETTI, L.M., "Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways", <u>Inflammation Research</u> , 46 Suppl. Vol. 2, pp. S143-4, 1997.	
M	28	ELHAGE, R. et al., "Differential Effects of Interleukin-1 Receptor antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in apolipoprotein E-Deficient Mice", <u>Circulation</u> , Vol. 97, No. 3, pp. 242-244, 1998.	
M	29	HOWELLS, G.L., "Cytokine networks in destructive periodontal disease", <u>Oral Diseases</u> , Vol. 1, pp. 266-270, 1995.	
M	30	HOLDEN, R.J. et al., "The Role of tumor Necrosis Factor- $\alpha$ in the Pathogenesis of anorexia and Bulimia Nervosa, Cancer Cachexia and Obesity", <u>Medical Hypotheses</u> , Vol. 47, pp. 423-438, 1996.	
M	31	BEISEL, W.R., "Herman Award Lecture, 1995: Infection-induced malnutrition-from cholera to cytokines", <u>Am. J. Clin. Nutr.</u> , Vol. 62, pp. 813-9, 1995.	
M	32	SALITURO, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases", <u>Current Medicinal Chemistry</u> , Vol. 6, pp. 807-823, 1999.	
M	33	FOSTER, M.L. et al., "Potential of p38 Inhibitors in the Treatment of Rheumatoid Arthritis", <u>Drug News Perspective</u> , Vol. 13, No. 8, pp. 488-497, 2000.	
M	34	ADAMS, J.L. et al., "Pyrimidinylimidazole Inhibitors of CSBP/P38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes", <u>Bioorganic &amp; Medicinal chemistry Letters</u> , Vol. 8, pp. 3111-3116, 1998.	
EXAMINER		V. Balasubramanian	DATE CONSIDERED 11/1/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.